CIRCA5000 | Roche
  B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised  
  B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised  
  B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised  
  B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised    B-Corporation Certified    Rated 4.5/5 on the app store    FCA Authorised  

Roche

By CIRCA5000 TeamBack to Mission Control

Impact in brief • 3 min read 

Roche

Today, millions of people live with chronic liver diseases such as fibrosis and cirrhosis. But many of these people have no idea these conditions put them at increased risk of liver cancer. 

That’s why pharmaceutical industry innovator Roche launched the One Liver program – an initiative aimed at tackling this problem head on. Every day, its expert teams work to understand liver disease and the challenges patients face.

The program brings together the collective knowledge and expertise of academic, medical, and industry partners across Asia, Africa, and Europe. Its ultimate goal is to disrupt disease trajectories and to cure liver cancer altogether.

One Liver program by Roche is aimed at disrupting disease trajectories and curing liver cancer altogether.

Now, Roche is planning to present data showing that one of its immunotherapy combinations improves overall survival in patients with a type of liver cancer. 

The analysis from the study showed that after an 8.6 month follow-up period, the risk of death reduced by a huge 42%.

It’s wins like this that keep teams at Roche focussed on finding new medicines that help patients live longer, better lives.

ROCHE QUICK FACTS

Founded in Switzerland in 1896, Roche is one of the world’s largest biotech companies, and is recognised as a leading provider of diagnostics and a global supplier of transformative innovative solutions across major disease areas. 

  • 28.9 million patients treated in 2020.
  • 23.4 billion tests were conducted with Roche diagnostic equipment in 2020.
  • 32 Roche medicines are on the WHO list of essential medicines.

PHARMA BREAKTHROUGH FUND IN NUMBERS

The value of your investments can go down as well as up and you may get back less than you originally invested. CIRCA5000 don't offer investment advice, if you're unsure if any investment is right for you please consult a suitably qualified financial adviser. The individual holdings of any fund offered by CIRCA5000 can change without warning.

Back To Mission Control

Invest in ahuman future

Desert Landscape